Clinical Trial to Evaluate the Tolerability and the Pharmacokinetics of CKD-348

A Phase I Clinical Trial to Evaluate the Tolerability and the Pharmacokinetics of CKD-348 With Co-administration of CKD-828, D097, and D337 in Healthy Adult Volunteers

A phase I clinical trial to evaluate the tolerability and the pharmacokinetics of CKD-348.

Study Overview

• Status: Completed
• Conditions: Hypertension and Dyslipidemia
• Intervention / Treatment: Drug: CKD-348(4) F1; Drug: CKD-348(4) F2; Drug: CKD-828, D097, D337

• Study Type: Interventional
• Enrollment (Actual): 32
• Phase: Phase 1

Contacts and Locations

Study Locations

• Korea, Republic of
  • Seoul, Korea, Republic of
    • H plus Yangji Hospital

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 19 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: Yes

Description

Inclusion Criteria:

1. Healthy adult volunteers aged ≥ 19 years
2. Weight ≥55kg with calculated body mass index (BMI) of 18 to 30 kg/m2

3. Those who meet the blood pressure criteria during screening tests:

   • Systolic Blood Pressure: 90 to 139 mmHg
   • Diastolic Blood Pressure: 60 to 89 mmHg
4. Those who have no congenital diseases or chronic diseases and have no abnormal symptoms or findings.
5. Those who are eligible for clinical trials based on laboratory (hematology, blood chemistry, serology, urology) and 1ECG results at screening.
6. Those who agree to contraception during the participation of clinical trial.
7. Individuals who voluntarily decide to participate and agree to comply with the cautions after fully understand the detailed description of this clinical trial.

Exclusion Criteria:

1. Those who received investigational products or participated in bioequivalence tests within 6 months before the first administration of clinical trial drugs.
2. Those who take barbiturate and any related drugs which may cause induction or inhibition of drug metabolism within 1 month and those who take drug could affect to clinical trial within 10 days before the first administration of investigational products.
3. Those who donated whole blood or apheresis within 8 weeks or 4 weeks respectfully, or received blood transfusion within a month.
4. Those who have a history of gastrointestinal surgery except simple appendectomy and hernia surgery.

5. Those who exceed an alcohol and cigarette consumption criteria write below within 1 month before the first administration of investigational products.

   • Alcohol: Man - 21 glasses/week Woman - 14 glasses/week (1 glass: Soju 50mL, Wine 30mL, or beer 250mL)
   • Smoking: 20 cigarettes/day
6. Those who have any history of diabetic mellitus, nephropathy, biliary obstruction, shock, angioedema, cardiac insufficiency, dihydropyridine sensitivity, unstable angina, hypothyroidism.
7. Those who have genetic problems such as galactose intolerance, Lapp lactose deficiency or glucose-galactose malabsorption.
8. Those who are deemed insufficient to participate in this clinical trial by investigators.
9. Woman who are pregnant or breastfeeding.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Crossover Assignment
• Masking: None (Open Label)

Number of Arms

6

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Sequence 1; Period 1: CKD-828, D097, D337- A single oral dose of 3 tablets under fasting condition Period 2: CKD-348(4) F1 - A single oral dose of 1 tablet under fasting condition Period 3: CKD-348(4) F2 - A single oral dose of 1 tablet under fasting condition	Drug: CKD-348(4) F1; QD, PQ; Drug: CKD-348(4) F2; QD, PQ; Drug: CKD-828, D097, D337; QD, PQ
Experimental: Sequence 2; Period 1: CKD-828, D097, D337- A single oral dose of 3 tablets under fasting condition Period 2: CKD-348(4) F2 - A single oral dose of 1 tablet under fasting condition Period 3: CKD-348(4) F1 - A single oral dose of 1 tablet under fasting condition	Drug: CKD-348(4) F1; QD, PQ; Drug: CKD-348(4) F2; QD, PQ; Drug: CKD-828, D097, D337; QD, PQ
Experimental: Sequence 3; Period 1: CKD-348(4) F1 - A single oral dose of 1 tablet under fasting condition Period 2: CKD-828, D097, D337- A single oral dose of 3 tablets under fasting condition Period 3: CKD-348(4) F2 - A single oral dose of 1 tablet under fasting condition	Drug: CKD-348(4) F1; QD, PQ; Drug: CKD-348(4) F2; QD, PQ; Drug: CKD-828, D097, D337; QD, PQ
Experimental: Sequence 4; Period 1: CKD-348(4) F1 - A single oral dose of 1 tablet under fasting condition Period 2: CKD-348(4) F2 - A single oral dose of 1 tablet under fasting condition Period 3: CKD-828, D097, D337- A single oral dose of 3 tablets under fasting condition	Drug: CKD-348(4) F1; QD, PQ; Drug: CKD-348(4) F2; QD, PQ; Drug: CKD-828, D097, D337; QD, PQ
Experimental: Sequence 5; Period 1: CKD-348(4) F2 - A single oral dose of 1 tablet under fasting condition Period 2: CKD-828, D097, D337- A single oral dose of 3 tablets under fasting condition Period 3: CKD-348(4) F1 - A single oral dose of 1 tablet under fasting condition	Drug: CKD-348(4) F1; QD, PQ; Drug: CKD-348(4) F2; QD, PQ; Drug: CKD-828, D097, D337; QD, PQ
Experimental: Sequence 6; Period 1: CKD-348(4) F2 - A single oral dose of 1 tablet under fasting condition Period 2: CKD-348(4) F1 - A single oral dose of 1 tablet under fasting condition Period 3: CKD-828, D097, D337- A single oral dose of 3 tablets under fasting condition	Drug: CKD-348(4) F1; QD, PQ; Drug: CKD-348(4) F2; QD, PQ; Drug: CKD-828, D097, D337; QD, PQ

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
AUCt of CKD-348(4) F1 and CKD-348(4) F2	AUCt: Area under the concentration-time curve from time zero to time	Pre-dose (0 hour), 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24, 48, 72 hours
Cmax of CKD-348(4) F1 and CKD-348(4) F2	Maximum plasma concentration of the drug	Pre-dose (0 hour), 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24, 48, 72 hours

Collaborators and Investigators

• Sponsor: Chong Kun Dang Pharmaceutical
• Investigators: Principal Investigator: Jaewoo Kim, M.D. Ph.D, m3116@newyjh.com

Study record dates

Study Major Dates

• Study Start (Actual): September 29, 2022
• Primary Completion (Actual): November 30, 2022
• Study Completion (Actual): December 9, 2022

Study Registration Dates

• First Submitted: September 18, 2022
• First Submitted That Met QC Criteria: September 18, 2022
• First Posted (Actual): September 22, 2022

Study Record Updates

• Last Update Posted (Actual): June 9, 2023
• Last Update Submitted That Met QC Criteria: June 7, 2023
• Last Verified: June 1, 2023

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Metabolic Diseases; Lipid Metabolism Disorders; Dyslipidemias
• Other Study ID Numbers: A86_11BE2218P

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No